The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

Also: All the news and watercooler chat from Fortune.

Dr. Albert Bourla became Pfizer’s CEO months before the COVID-19 pandemic took hold of the US. Under his leadership, Pfizer manufactured 3 billion doses of the first FDA-approved vaccine in the first ...

The Food and Drug Administration may revoke authorization for Pfizer’s COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...

WASHINGTON — U.S. regulators approved updated COVID-19 shots Wednesday but limited their use for many Americans — and removed one of the two vaccines available for young children. The new shots from ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its COVID-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to ...

New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...

U.S. regulators approved Pfizer’s updated COVID-19 shot Wednesday but with limits that could complicate access for millions of American adults and children.Pfizer said in a release its vaccine is now ...